Jean-Philippe Durand

1.6k total citations
50 papers, 1.2k citations indexed

About

Jean-Philippe Durand is a scholar working on Oncology, Physiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jean-Philippe Durand has authored 50 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 13 papers in Physiology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jean-Philippe Durand's work include Colorectal Cancer Treatments and Studies (14 papers), Cancer Treatment and Pharmacology (12 papers) and Nutrition and Health in Aging (12 papers). Jean-Philippe Durand is often cited by papers focused on Colorectal Cancer Treatments and Studies (14 papers), Cancer Treatment and Pharmacology (12 papers) and Nutrition and Health in Aging (12 papers). Jean-Philippe Durand collaborates with scholars based in France, United States and Netherlands. Jean-Philippe Durand's co-authors include François Goldwasser, Romain Coriat, Olivier Mir, Pascaline Boudou‐Rouquette, Stanislas Ropert, Benoı̂t Blanchet, Michel Vidal, Jérôme Alexandre, François Goldwasser and Stanislas Chaussade and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and American Journal of Clinical Nutrition.

In The Last Decade

Jean-Philippe Durand

46 papers receiving 1.2k citations

Peers

Countries citing papers authored by Jean-Philippe Durand

Since Specialization

Citations

This map shows the geographic impact of Jean-Philippe Durand's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean-Philippe Durand with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean-Philippe Durand more than expected).

Fields of papers citing papers by Jean-Philippe Durand

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean-Philippe Durand. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean-Philippe Durand. The network helps show where Jean-Philippe Durand may publish in the future.

Co-authorship network of co-authors of Jean-Philippe Durand

This figure shows the co-authorship network connecting the top 25 collaborators of Jean-Philippe Durand. A scholar is included among the top collaborators of Jean-Philippe Durand based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean-Philippe Durand. Jean-Philippe Durand is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Relationship between energetic gap and sensitivity to anti-programmed cell death 1 immune checkpoint inhibitors in non-small cell lung cancer patients: The ELY-2 study 2024 ·Clinical Nutrition ESPEN ·(unknown), Pascaline Boudou‐Rouquette, Jennifer Arrondeau, (unknown), Laure Hirsch, N. Neveux, Elizabeth Fabre, (unknown), Diane Damotte, Marie Wislez, Jérôme Alexandre, Jean-Philippe Durand, (unknown), François Goldwasser	2
2	Association of Energy Expenditure and Efficacy in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab 2022 ·Cancers ·(unknown), Anne Jouinot, Jérôme Alexandre, (unknown), Marie Bretagne, (unknown), (unknown), (unknown), Marie‐Pierre Revel, Michaël Peyromaure, Pascaline Boudou‐Rouquette, Jennifer Arrondeau, (unknown), Jean-Philippe Durand, François Goldwasser, Olivier Huillard	2
3	Relationship between the creatinine/cystatin C ratio and muscle mass measured by CT-scan in cancer patients 2022 ·Clinical Nutrition ESPEN ·Camille Tlemsani, Jean-Philippe Durand, Bruno Raynard, Marie‐Pierre Revel, Élise Deluche, Mario Di Palma, F. Pigneur, François Goldwasser	15
4	Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study 2021 ·EBioMedicine ·Pascaline Boudou‐Rouquette, Jennifer Arrondeau, Claire Gervais, Jean-Philippe Durand, Elizabeth Fabre, (unknown), (unknown), (unknown), (unknown), (unknown), Diane Damotte, Audrey Mansuet‐Lupo, Frédérique Giraud, Marco Alifano, Marie Wislez, Jérôme Alexandre, Anne Jouinot, François Goldwasser	10
5	Creatinine-to-cystatin C ratio and bioelectrical impedance analysis for the assessement of low lean body mass in cancer patients: Comparison to L3–computed tomography scan 2020 ·Nutrition ·(unknown), (unknown), Jean-Philippe Durand, N. Neveux, Anne Jouinot, Jean‐Pascal De Bandt, François Goldwasser, Luc Cynober	33
6	Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patients 2019 ·Clinical Nutrition ·Anne Jouinot, (unknown), (unknown), Jean-Philippe Durand, Pascaline Boudou‐Rouquette, Jennifer Arrondeau, Camille Tlemsani, Ludovic Fournel, Marco Alifano, Marie Wislez, Jeanne Chapron, (unknown), Audrey Mansuet‐Lupo, Diane Damotte, N. Neveux, Jean‐Pascal De Bandt, Jérôme Alexandre, Luc Cynober, François Goldwasser	26
7	Estimation of glomerular filtration rate in patients with abnormal body composition and relation with carboplatin toxicity 2016 ·Annals of Oncology ·Marie Bretagne, Anne Jouinot, Jean-Philippe Durand, Camille Tlemsani, Jennifer Arrondeau, Olivier Huillard, (unknown), François Goldwasser, J M Alexandre	1
8	Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics 2015 ·Expert Opinion on Investigational Drugs ·Jennifer Arrondeau, Olivier Huillard, Camille Tlemsani, Anatole Cessot, Pascaline Boudou‐Rouquette, Benoı̂t Blanchet, Audrey Thomas‐Schoemann, Michel Vidal, Jean‐Marie Tigaud, Jean-Philippe Durand, Jérôme Alexandre, François Goldwasser	7
9	Effect of integrated palliative care on the quality of end-of-life care: retrospective analysis of 521 cancer patients 2012 ·BMJ Supportive & Palliative Care ·Isabelle Colombet, (unknown), Jean-Philippe Durand, Florence Gillaizeau, Ralph Niarra, (unknown), Jérôme Alexandre, François Goldwasser, (unknown)	29
10	Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma 2012 ·PLoS ONE ·Olivier Mir, Romain Coriat, Benoı̂t Blanchet, Jean-Philippe Durand, Pascaline Boudou‐Rouquette, Judith Michels, Stanislas Ropert, Michel Vidal, Stanislas Pol, Stanislas Chaussade, François Goldwasser	242
11	Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib 2012 ·Medical Oncology ·Olivier Mir, Romain Coriat, Pascaline Boudou‐Rouquette, Stanislas Ropert, Jean-Philippe Durand, Anatole Cessot, Vincent Mallet, Philippe Sogni, Stanislas Chaussade, Stanislas Pol, François Goldwasser	34
12	Early Sorafenib-Induced Toxicity Is Associated with Drug Exposure and UGTIA9 Genetic Polymorphism in Patients with Solid Tumors: A Preliminary Study 2012 ·PLoS ONE ·Pascaline Boudou‐Rouquette, Céline Narjoz, Jean Louis Golmard, Audrey Thomas‐Schoemann, Olivier Mir, Fabrice Taïeb, Jean-Philippe Durand, Romain Coriat, Alain Dauphin, Michel Vidal, Michel Tod, Marie‐Anne Loriot, François Goldwasser, Benoı̂t Blanchet	85
13	Feasibility of gemcitabine and oxaliplatin in patients with advanced biliary tract carcinoma and a performance status of 2 2012 ·Anti-Cancer Drugs ·Olivier Mir, Romain Coriat, Marion Dhooge, Géraldine Perkins, Pascaline Boudou‐Rouquette, Catherine Brézault, Stanislas Ropert, Jean-Philippe Durand, Stanislas Chaussade, François Goldwasser	17
14	Validation of the Cochin Risk Index Score (CRIS) for life expectancy prediction in terminally ill cancer patients 2011 ·Supportive Care in Cancer ·Jean-Philippe Durand, Olivier Mir, Romain Coriat, Anatole Cessot, (unknown), François Goldwasser	13
15	Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial 2011 ·Annals of Oncology ·Jean-Philippe Durand, G. Deplanque, (unknown), J.M. Gornet, F. Scotté, Olivier Mir, Anatole Cessot, Romain Coriat, Éric Raymond, Emmanuel Mitry, Patrice Herait, Y. Yataghene, François Goldwasser	144
16	Safety of bevacizumab 7.5 mg/kg infusion over 10 minutes in NSCLC patients 2011 ·Investigational New Drugs ·Olivier Mir, Jérôme Alexandre, Romain Coriat, Stanislas Ropert, Pascaline Boudou‐Rouquette, (unknown), Jeanne Chapron, Jean-Philippe Durand, Daniel Dusser, François Goldwasser	7
17	Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients 2010 ·Investigational New Drugs ·Romain Coriat, Olivier Mir, Anatole Cessot, Catherine Brézault, Stanislas Ropert, Jean-Philippe Durand, Wulfran Cacheux, Stanislas Chaussade, François Goldwasser	20
18	Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience 2009 ·Anti-Cancer Drugs ·Olivier Mir, Jérôme Alexandre, Stanislas Ropert, (unknown), (unknown), Jean-Philippe Durand, François Goldwasser	11
19	Dramatic recovery of paclitaxel-disabling neurosensory toxicity following treatment with venlafaxine 2002 ·Anti-Cancer Drugs ·Jean-Philippe Durand, François Goldwasser	27
20	Oncologie: étude sur la prévalence des cancers du nasopharynx à Yaoundé (Cameroun) 1986 ·(unknown), Gaoussou Touré, (unknown), (unknown), (unknown), Jean-Philippe Durand	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact